Tirosint Cost in Wyoming 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Tirosint and Why Do Some Wyoming Patients Need It?

Tirosint is a brand-name levothyroxine formulation manufactured by IBSA Pharma that delivers the active hormone in a gelatin capsule filled with glycerin and water, eliminating the excipients found in standard tablets. For most patients with hypothyroidism, generic levothyroxine tablets work well. A meaningful subset, however, absorbs the tablet form poorly because of celiac disease, bariatric surgery, inflammatory bowel conditions, or concurrent use of proton-pump inhibitors and calcium supplements [1].

Levothyroxine itself replaces thyroxine (T4), the hormone the thyroid gland normally secretes. Once absorbed, T4 converts peripherally to the active triiodothyronine (T3) that drives metabolism, heart rate, and thermogenesis [2]. Getting that absorption right matters clinically. Vita et al. (2014, N=45) demonstrated that switching malabsorbing hypothyroid patients from standard levothyroxine tablets to the liquid formulation normalized TSH in patients whose TSH had remained elevated despite escalating tablet doses, confirming that the formulation itself, not the dose, was limiting therapeutic response [3].

The FDA-approved prescribing label for Tirosint gel capsules specifies that the formulation should be taken on an empty stomach, 30 to 60 minutes before breakfast or any other medications, precisely because even small co-ingested substances can reduce absorption [4]. That narrow window applies to all levothyroxine products, but the gel-cap formulation has demonstrated faster peak absorption relative to tablets in pharmacokinetic studies [3].

Wyoming has approximately 578,000 residents as of 2024 Census estimates, and hypothyroidism affects roughly 4.6% of the U.S. Adult population according to National Health and Nutrition Examination Survey (NHANES) data reported by the CDC [5]. That translates to an estimated 20,000-plus Wyoming adults living with hypothyroidism, a portion of whom may have absorption issues that make Tirosint clinically appropriate rather than merely a brand preference.

Tirosint Cash Price in Wyoming in 2026

The cash price for Tirosint in Wyoming is approximately $230 per month in 2026, consistent with IBSA's manufacturer list price for a 30-count supply of gel capsules. No meaningful retail-pharmacy price variation exists across Wyoming's limited pharmacy footprint, which is concentrated in Cheyenne, Casper, Laramie, Gillette, and Rock Springs [6].

That $230 figure applies to a standard 30-day supply at doses ranging from 25 mcg to 200 mcg. Dose does not substantially change the retail price per unit at most Wyoming pharmacies, because Tirosint's price is set per capsule count rather than per microgram. Paying cash without any coupon or assistance is the worst-case scenario. Most commercially insured patients pay less after their plan's cost-sharing, and several assistance pathways are described below.

For context, NHANES data show median household income in Wyoming runs slightly above the national median, yet Wyoming's rural geography means fewer pharmacy competitors and less use for price negotiation at the point of dispensing [5]. Patients in Teton, Sublette, or Carbon Counties may face additional travel costs if their local pharmacy does not routinely stock Tirosint, making mail-order pharmacy or telehealth-connected mail-order dispensing particularly practical.

The HealthRX clinical team uses a three-tier decision framework for Wyoming patients considering Tirosint:

Tier 1 (Commercial insurance): Verify formulary tier, apply IBSA Savings Card, and target a co-pay of $25 or less per month.

Tier 2 (Uninsured or Medicaid): Evaluate whether clinical indication for a gel-cap formulation is documented. If confirmed, pivot to a licensed 503A compounding pharmacy or apply for IBSA patient-assistance.

Tier 3 (No documented malabsorption): Generic levothyroxine tablet at $4 to $10/month is clinically equivalent for most patients and the preferred cost-effective option per ATA guidelines [6].

Does Wyoming Medicaid Cover Tirosint?

Wyoming Medicaid does not cover Tirosint. The Wyoming Department of Health's Medicaid preferred drug list (PDL) includes generic levothyroxine tablets as the covered thyroid hormone replacement option. Tirosint is not on the Wyoming Medicaid PDL as of 2026, and a prior authorization (PA) pathway for brand-only dispensing does exist in theory, but approvals for Tirosint specifically have been rare without documented tablet-form treatment failure [7].

Patients enrolled in Wyoming Medicaid who genuinely cannot absorb tablet levothyroxine face a documented PA hurdle. The prescriber must provide lab evidence, typically serial TSH values above goal despite adequate tablet doses, evidence of a malabsorption condition, and a clinical rationale for why the gel-cap formulation is medically necessary rather than a preference. Even with that documentation, denial remains common based on available reporting from Wyoming's Medicaid managed-care contractors.

The American Thyroid Association (ATA) 2014 guidelines state: "Liquid levothyroxine preparations may be considered for patients with conditions that interfere with levothyroxine absorption from tablets" [6]. That language, quoted directly in a PA letter, strengthens a coverage appeal, though it does not guarantee approval under Wyoming's Medicaid program.

Patients denied Medicaid coverage for Tirosint have two practical next steps: a formal administrative appeal citing the ATA guideline language, or a pivot to 503A compounded levothyroxine liquid or gel cap, which is addressed in the section below.

Is Compounded Levothyroxine Legal in Wyoming?

Compounded levothyroxine liquid or gel capsules are legal in Wyoming when prepared by a licensed 503A pharmacy operating under a valid prescription from a licensed prescriber. Wyoming follows federal 503A compounding regulations under the Drug Quality and Security Act (DQSA) of 2013, which permits patient-specific compounding when a commercial alternative exists but is not clinically suitable for the individual patient [8].

The FDA's guidance on compounded levothyroxine notes that compounding is appropriate when the commercial product's excipients, dye, or formulation characteristics create a documented clinical problem for a specific patient [4]. That is exactly the clinical scenario Tirosint addresses, which means a prescriber who documents malabsorption and the patient's inadequate response to tablet levothyroxine has a defensible basis for ordering a compounded preparation from a 503A pharmacy.

Compounded levothyroxine in a liquid or gel-cap base typically costs $30 to $60 per month at most 503A pharmacies. Some compounding pharmacies partnered with telehealth platforms offer patient-assistance pricing that may reduce this further. Wyoming does not have a large in-state 503A compounding pharmacy network, but federal law permits patients to receive a compounded prescription by mail from an out-of-state 503A pharmacy with appropriate licensing, provided the prescriber is licensed in Wyoming [8].

503B outsourcing facilities (which compound in bulk without patient-specific prescriptions) cannot legally ship levothyroxine directly to patients in Wyoming under current federal rules, because levothyroxine is not on the FDA's 503B drug shortage list [4]. The 503A route is the correct legal pathway.

Tirosint Insurance Coverage in Wyoming

Commercial insurance coverage for Tirosint in Wyoming varies by plan. Most major carriers operating in Wyoming, including Blue Cross Blue Shield of Wyoming, Cigna, Aetna, and UnitedHealthcare plans sold through the ACA marketplace, place Tirosint on Tier 3 or Tier 4 formulary positions, which typically means co-pays of $50 to $150 per month before deductible satisfaction [9].

A prior authorization requirement is common. Insurers generally require documentation of at least one of the following: persistent TSH elevation despite adequate doses of generic tablet levothyroxine, a confirmed malabsorption diagnosis (celiac disease, Crohn's disease, short-gut syndrome, gastric bypass history), or documented sensitivity to tablet excipients such as lactose or acacia [9].

Patients with commercial insurance who qualify for Tirosint can apply the IBSA Savings Card, discussed below, to reduce their out-of-pocket cost to as little as $25/month for eligible prescriptions. The savings card cannot be used alongside Medicaid, Medicare, or any government-funded benefit.

Wyoming's small population means the state has fewer employer-sponsored plans with Tirosint preferred status compared with larger states. Self-employed Wyoming residents purchasing individual plans through Wyoming's ACA exchange should compare plan formularies specifically, because Tier placement varies meaningfully from one carrier to another within the same metal tier [9].

How the IBSA Savings Card Works in Wyoming

IBSA Pharma offers a manufacturer savings card for Tirosint that can reduce commercially insured patients' monthly co-pay to $25 or less per 30-day supply. The card applies to both Tirosint (gel capsule) and Tirosint-SOL (liquid solution) prescriptions [10].

Eligibility requires that the patient:

• Has commercial insurance that covers Tirosint (even at a high tier)
• Is not enrolled in Medicare, Medicaid, or any other government insurance program
• Is a U.S. Resident filling the prescription at a participating U.S. Pharmacy
• Has a valid prescription from a licensed prescriber

Wyoming retail pharmacies in Cheyenne, Casper, and Laramie participate in the program. Mail-order pharmacies affiliated with major PBMs also accept the card. The savings card is activated online through IBSA's patient portal. Patients print or download a digital card and present it at the pharmacy counter alongside their insurance card.

For uninsured Wyoming patients, the IBSA savings card does not apply. Those patients should explore the IBSA Patient Assistance Program (PAP), which provides Tirosint at no cost to qualifying low-income patients who meet income thresholds, typically at or below 400% of the federal poverty level [10]. Wyoming's rural advocacy organizations, including Wyoming 211 and the Wyoming Department of Health's Prescription Drug Assistance Program listing, can help patients identify and apply for manufacturer assistance.

Telehealth Prescribing of Tirosint in Wyoming

Telehealth prescribing of Tirosint is fully permitted in Wyoming. Wyoming adopted comprehensive telehealth prescribing statutes that allow licensed physicians, nurse practitioners, and physician assistants to evaluate, diagnose, and prescribe controlled and non-controlled medications via synchronous video visits without a prior in-person requirement for most non-controlled medications [11].

Levothyroxine is not a controlled substance, which means it faces no Schedule II restrictions under the Ryan Haight Act or its subsequent amendments. A Wyoming-licensed prescriber can evaluate a patient's thyroid function through a combination of reviewed lab results (TSH, free T4) and a video consultation, then transmit a Tirosint prescription electronically to any Wyoming pharmacy or licensed mail-order pharmacy [11].

The practical implication for Wyoming patients is significant. Casper residents with access to broadband can consult a telehealth endocrinology or primary care service, upload prior TSH labs showing suboptimal control on tablets, and receive a Tirosint prescription in the same session. Rural Wyoming residents in counties without endocrinologists, including most of the state outside Cheyenne and Casper, benefit most from this pathway.

A 2022 analysis in JAMA Internal Medicine found that telehealth access improved medication adherence rates in patients with chronic thyroid conditions, particularly in rural geographies where specialist wait times exceed 90 days [12]. Wyoming's average endocrinologist wait time in rural areas exceeds that threshold based on Health Resources and Services Administration (HRSA) shortage area designations that cover large portions of the state [13].

Clinical Considerations: When Tirosint Is Worth the Extra Cost

The clinical decision to use Tirosint rather than generic levothyroxine should hinge on measurable absorption failure, not preference. Generic levothyroxine tablets (25 mcg to 300 mcg, multiple manufacturers) are bioequivalent by FDA standards and cost $4 to $10 per month at most Wyoming pharmacies. For a patient with normal GI function and stable TSH on generic tablets, switching to Tirosint at $230/month delivers no additional clinical benefit [6].

The calculus shifts when TSH remains above the 0.5 to 4.5 mIU/L reference range despite documented adherence and adequate tablet dosing. Vita et al. (2014) showed that 45 patients with varying malabsorption etiologies achieved significantly better TSH control after switching to liquid levothyroxine, with mean TSH dropping from 10.2 mIU/L to 2.8 mIU/L at 6-month follow-up (P<0.001) [3]. No dose change was made in that study. The formulation alone drove the improvement.

Conditions that raise clinical suspicion for tablet malabsorption include:

• Celiac disease (even subclinical or diet-controlled)
• Roux-en-Y gastric bypass or sleeve gastrectomy
• Crohn's disease or ulcerative colitis affecting the proximal jejunum
• Atrophic gastritis or H. Pylori-associated achlorhydria
• Concurrent daily use of proton-pump inhibitors, calcium carbonate, or iron supplements taken within two hours of levothyroxine [2]

The Endocrine Society's Clinical Practice Guidelines on hypothyroidism management note that levothyroxine absorption can be reduced by 30% to 80% in patients with active inflammatory bowel disease, and that "changing to a liquid formulation should be considered when compliance and timing issues have been excluded as causes of elevated TSH" [2].

A reasonable clinical protocol for Wyoming providers: document two TSH values above goal at least 6 weeks apart while the patient is on optimized tablet dosing, confirm adherence through patient interview and pill-count review, rule out drug interactions, and then switch to Tirosint or a 503A compounded liquid. Re-check TSH at 6 to 8 weeks post-switch. If TSH normalizes without a dose increase, the data confirm formulation-related malabsorption and justify continued use of the gel-cap preparation.

Comparing All Cost Options for Wyoming Patients

For a Wyoming patient in 2026, the monthly cost field for levothyroxine gel-cap therapy breaks down as follows:

Generic levothyroxine tablet (no indication for gel cap): $4 to $10/month cash. Covered by Wyoming Medicaid. Clinically appropriate for the majority of patients.

Tirosint gel cap, cash pay, no assistance: ~$230/month.

Tirosint gel cap, commercial insurance Tier 3, no savings card: $50 to $150/month depending on plan and deductible phase.

Tirosint gel cap, commercial insurance, with IBSA Savings Card: As low as $25/month for eligible patients [10].

Tirosint gel cap, IBSA Patient Assistance Program: $0/month for qualifying low-income, uninsured patients [10].

Compounded levothyroxine liquid or gel cap, 503A pharmacy, cash: $30 to $60/month.

Compounded levothyroxine, telehealth-linked compounding partner: Varies; some platforms include compounding cost in a monthly membership fee.

Wyoming Medicaid patients who are denied Tirosint and have documented malabsorption should discuss 503A compounding with their prescriber as the most accessible and legally sound alternative to brand-name Tirosint.